November is National Epilepsy Awareness Month – a milestone that allows us to pause and reflect on both the progress the community has made for people living with this condition and their continued unmet needs. This time of reflection is especially important for people diagnosed with rare forms of epilepsy, as well as their families and caregivers, who are continuing to search for improved therapeutic outcomes.
Recently, Mat Davis, PhD, vice president and head of data science, presented at the 2023 STAT Summit where he shared a key moment in his career when he learned the necessity of breaking down silos to fully embrace quantitative experts across the three avenues of drug development.
Jazz’s oncology efforts are focused on delivering innovation to improve patient care, quality of life, and advancing scientific understanding of cancers with high unmet needs like acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), which often affect children. To learn more about progress in the fight against these childhood blood cancers, Jazz’s Abizer Gaslightwala spoke with pediatric hematologist/oncologist Dr. Rachel Rau.
As World Heart Day approaches, we are reminded of people who live with complex sleep disorders and how we can adequately address their unique needs. Learn more about the importance of thinking holistically about narcolepsy and idiopathic hypersomnia patients’ health from Jazz’s Dr. Kelvin Tan and Dr. Logan Schneider of the Stanford University School of Medicine.
For 20 years, Jazz has been focused on ensuring patients have innovative treatments for rare, hard-to-treat disorders. We have done this in part by expanding the science behind existing options to create new or better standards of care in challenging diseases such as narcolepsy, idiopathic hypersomnia, and other sleep disorders.
As a leader in sleep medicine, Jazz’s nearly 20-year leadership has been built around tackling rare sleep conditions, all while centering on and giving a voice to the patient and caregiver experiences, such as those living with idiopathic hypersomnia. Read more about our plans to expand and spotlight the I Have IH awareness campaign at SLEEP 2023.
Thank you! We'll get back to you shortly.
Please select and enter the required fields on the form below. We need this information to process your request and to take necessary steps to verify your identity.
We will contact you if we need any additional information
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.